How much does a box of Capmatinib cost?

Capmatinib (Capmatinib) is an oral therapeutic drug that belongs to the tyrosine kinase inhibitor (TKI) class. It is primarily used to treat a specific subpopulation of patients with non-small cell lung cancer (NSCLC), namely those who carry METexon14 skipping mutations.

Capmatinib is not currently on the market in China, so patients cannot purchase it domestically. Capmatinib abroad is divided into original drugs and generic drugs. The original drug is mainly the original drug from Novartis, with a price of about 35,000 yuan and a specification of 200mg*60; the price of generic drugs is very cheap, mainly Laos generic drugs, with a price of about 3,000 to 4,000 yuan. The ingredients of original drugs and generic drugs are basically the same.

METexon14 skipping mutation is a rare but clinically significant gene mutation that leads to abnormal activation of the MET receptor. MET is an important receptor kinase that regulates biological processes such as cell proliferation, migration, and survival. When METkinase is abnormally activated, it may promote the growth and spread of cancer cells, leading to the progression of NSCLC.

Capmatinib blocks the proliferation of cancer cells by inhibiting the activity ofMETkinase and interfering with the conduction of abnormal signaling pathways. By targeting patients with METexon 14 skipping mutations, capmatinib provides these patients with a treatment option to slow or inhibit cancer progression.

The drug has undergone clinical trials and has received approval from some regulatory agencies for the treatment of patients with advanced NSCLC with METexon14 skipping mutations. However, like all medications, it may have some side effects and risks. Therefore, patients should undergo careful evaluation and guidance from a medical professional before using capmatinib or any other drug.